The content on this site is intended for healthcare professionals only
Dr Jane Meisel comments on Dr Hope Hugo's study on the use of sacituzumab govitecan (trodelvy) an antibody-drug conjugate which resulted in longer progression-free survival compared to the physician’s choice of chemotherapy in patients who have received many prior therapies and who had hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer.
Dr Meisel discusses the significance of the study for estrogen positive endocrine resistant patients stating that this has previously been an area of great unmet need.
Reflecting on the results of the study, she concludes that sacituzumab govitecan tends to work better than chemotherapy when compared, then goes onto highlight the study as 'a step forward for the field.'
Read the article here
Watch the press conference here
Watch the interview here
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
SABCS 2023: Highlights
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection
